HDx enabled by Theranova

The next evolution in hemodialysis

Connect with us
Theranova

Expanded Hemodialysis (HDx) enabled by the Theranova dialyzer brings us one step closer to the natural kidney1

  

Theranova membrane removing large middle molecules

Remove large middle molecules while maintaining stable albumin levels

The unique membrane of the Theranova dialyzer delivers superior removal of conventional/large middle molecules (up to 45,000 Da),1-5 compared to high-flux membranes, while selectively retaining essential proteins and maintaining stable albumin levels.4,6,7

Reduce hospitalizations

Choosing the Theranova dialyzer may reduce hospitalizations by 45%

An analysis of a randomized controlled trial of US hemodialysis patients showed that all-cause hospitalizations were 45% lower in patients treated with the Theranova dialyzer compared to patients treated with high-flux HD (p = 0.042).8

Man with granddaughter

Theranova may improve quality of life

The Theranova dialyzer may improve patient-reported kidney disease Quality of Life (QoL) outcomes including symptom burden, restless leg syndrome (RLS) criteria, uremic pruritus, and dialysis recovery time.2,9,10

See how Theranova works

Watch the video to see how the Theranova dialyzer brings us a step closer to the natural kidney.1

HDxcellence Academy

HDxcellence Academy

Access our on-demand video library of short (5-15 minutes) modules delivered by experts on topics such as:

• Medium Cut-Off (MCO) dialyzers like Theranova that bring us one step closer to the natural kidney1 

• Pathological role that conventional/large middle molecular toxins (up to 45,000 Da) play in the development of uremic clinical syndrome  

• Evidence surrounding clinical effectiveness, safety and efficacy, patient-reported Quality of Life and health economic outcomes related to HDx therapy

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

Rx Only. For the safe and proper use of this device, refer to the Instructions for Use.

 

Baxter and Theranova are trademarks of Baxter International Inc. or its subsidiaries.